By Genevra Pittman NEW YORK (Reuters Health) – Women who eat a lot of fat, particularly saturated fat, may be at higher risk of certain types of breast cancer, new research suggests. Past studies have come to differing conclusions on a possible association between dietary fat and breast cancer. Still, it cannot prove that a high-fat diet is the reason any of the women got cancer. “In our study we confirm that saturated fat intake was positively associated with breast cancer risk,” lead author Sabina Sieri, from the Fondazione IRCCS National Cancer Institute in Milan, Italy, told Reuters Health in an email.

By Dorene Internicola NEW YORK (Reuters) – Strength training, traditionally favored by body builders seeking to bulk up, has become the go-to regimen for athletes, weekend warriors and exercise enthusiasts determined to slim down. Fitness experts say metabolic strength training, a high-intensity, full-body interval workout, can add definition to the shape of runners, cyclists and other cardio devotees willing to put some muscle into it. Florida-based trainer Nick Tumminello believes strength training should be the primary form of exercise for everyone except beginners. “If you’re looking to lose fat, go with strength training,” said Tumminello, author of “Strength Training for Fat Loss.” “Watch your diet to reveal your shape, and strength train to improve that shape.” It is not your grandfather’s body-building program.

By Gus Trompiz PARIS (Reuters) – The purchase of Novartis’ animal-health business will strengthen Eli Lilly’s hand in emerging markets, tapping into growing demand there for protein-rich diets and household treatments for pets, a senior executive at the U.S. group said. As part of a multi-billion dollar revamp announced earlier on Tuesday, Swiss drugmaker Novartis said it would sell its animal-health arm to Lilly for about $5.4 billion, while also swapping assets with GlaxoSmithKline . Lilly said the deal would turn its Elanco unit from the world’s No. 4 animal-health group by revenue to the global No. 2 in a sector that supplies medicines, vaccines and feed additives for farm and domestic animals. “This deal really allows us to get a significant increase in our footprint in emerging markets and in our protein business on the food animal side this will be very important for us,” Jeff Simmons, Eli Lilly’s senior vice president and president of Elanco, told Reuters.

Title: Appetite, Taste Changes Reported After Weight-Loss Surgery
Category: Health News
Created: 4/18/2014 12:35:00 PM
Last Editorial Review: 4/21/2014 12:00:00 AM

By Solarina Ho TORONTO (Reuters) – Canada’s main stock index was little changed in thin Easter holiday trading on Monday with drops in Barrick Gold Corp and TransCanada Corp , which was hit by another delay for its Keystone XL pipeline project, offsetting gains in other groups. TransCanada was the biggest drag on the index, closing down 3.7 percent at C$49.38 after the Obama administration again delayed a decision on whether to approve the Keystone project. The TSX index’s energy group, of which TransCanada is a part, was off 0.05 percent. The heavily weighted materials group, home to gold miners, was down 0.4 percent, hurt by Barrick, which fell 3.9 percent to C$19.03.

By Dorene Internicola NEW YORK (Reuters) – Strength training, traditionally favored by body builders seeking to bulk up, has become the go-to regimen for athletes, weekend warriors and exercise enthusiasts determined to slim down. Fitness experts say metabolic strength training, a high-intensity, full-body interval workout, can add definition to the shape of runners, cyclists and other cardio devotees willing to put some muscle into it. Florida-based trainer Nick Tumminello believes strength training should be the primary form of exercise for everyone except beginners. “If you’re looking to lose fat, go with strength training,” said Tumminello, author of “Strength Training for Fat Loss.” “Watch your diet to reveal your shape, and strength train to improve that shape.” It is not your grandfather’s body-building program.

Experts say that dieters who include apps in their weight-loss efforts score greater success than those who don’t. We asked three Health readers to each test a leading digital diet and report back.

By Kathryn Doyle NEW YORK (Reuters Health) – For people recently diagnosed with type 2 diabetes, eating lots of olive oil, fish and whole grains slows progression of the disease more than restricting fat, according to a new analysis. In a trial that followed participants for more than eight years, those following a so-called Mediterranean diet went significantly longer before needing diabetes medication and more of them had their diabetes go into remission, compared to those on a low-fat diet. “There’s been lots of epidemiology suggesting that a Mediterranean diet was beneficial with metabolic syndrome and diabetes,” Dr. Leanne Olansky told Reuters Health. “But this was a randomized controlled trial, so we know it really was the diet causing the results,” she said.

By Svea Herbst-Bayliss BOSTON (Reuters) – Illinois Attorney General Lisa Madigan’s office said on Thursday it is investigating Herbalife, joining other state and federal probes of allegations that the weight loss and nutrition company is running a pyramid scheme. Madigan’s office was urged to look into the company months ago by civil rights groups, which claimed it was a pyramid scheme targeting minorities. Hedge fund manager William Ackman was the first to call Herbalife a fraud and placed a $1 billion bet against the company in 2012. The company denies the allegations, and high-profile investors such as Carl Icahn, George Soros and Dan Loeb have supported the company in the past by taking stakes.

Jacques Servier, founder and president of France’s second-largest drugmaker, has died before his trial over Mediator, a weight-loss pill at the center of the country’s biggest public health scandal in years. Servier died of old age, a company spokeswoman said on Thursday. Officials have blamed at least 500 deaths on Mediator, which was marketed to overweight diabetics but often prescribed for weight loss. Servier posted revenue of 4.2 billion euros ($5.8 billion) in 2013, making it France’s second-biggest drugmaker by sales behind Sanofi.